Literature DB >> 19011621

Arginine methylation regulates the p53 response.

Martin Jansson1, Stephen T Durant, Er-Chieh Cho, Sharon Sheahan, Mariola Edelmann, Benedikt Kessler, Nicholas B La Thangue.   

Abstract

Activation of the p53 tumour suppressor protein in response to DNA damage leads to apoptosis or cell-cycle arrest. Enzymatic modifications are widely believed to affect and regulate p53 activity. We describe here a level of post-translational control that has an important functional consequence on the p53 response. We show that the protein arginine methyltransferase (PRMT) 5, as a co-factor in a DNA damage responsive co-activator complex that interacts with p53, is responsible for methylating p53. Arginine methylation is regulated during the p53 response and affects the target gene specificity of p53. Furthermore, PRMT5 depletion triggers p53-dependent apoptosis. Thus, methylation on arginine residues is an underlying mechanism of control during the p53 response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19011621     DOI: 10.1038/ncb1802

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  229 in total

1.  Type II arginine methyltransferase PRMT5 regulates gene expression of inhibitors of differentiation/DNA binding Id2 and Id4 during glial cell differentiation.

Authors:  Jinghan Huang; Gillian Vogel; Zhenbao Yu; Guillermina Almazan; Stéphane Richard
Journal:  J Biol Chem       Date:  2011-10-31       Impact factor: 5.157

2.  Structural insights into protein arginine symmetric dimethylation by PRMT5.

Authors:  Litao Sun; Mingzhu Wang; Zongyang Lv; Na Yang; Yingfang Liu; Shilai Bao; Weimin Gong; Rui-Ming Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

3.  Proteomic dissection of the von Hippel-Lindau (VHL) interactome.

Authors:  Yanlai Lai; Meihua Song; Kevin Hakala; Susan T Weintraub; Yuzuru Shiio
Journal:  J Proteome Res       Date:  2011-10-11       Impact factor: 4.466

Review 4.  Posttranslational modification of p53: cooperative integrators of function.

Authors:  David W Meek; Carl W Anderson
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

5.  MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output.

Authors:  Lihong Chen; Zhenyu Li; Aleksandra K Zwolinska; Matthew A Smith; Brittany Cross; John Koomen; Zhi-Min Yuan; Thomas Jenuwein; Jean-Christophe Marine; Kenneth L Wright; Jiandong Chen
Journal:  EMBO J       Date:  2010-06-29       Impact factor: 11.598

Review 6.  Small Molecule Inhibitors of Protein Arginine Methyltransferases.

Authors:  Hao Hu; Kun Qian; Meng-Chiao Ho; Y George Zheng
Journal:  Expert Opin Investig Drugs       Date:  2016-02-16       Impact factor: 6.206

7.  Evolutionary emergence of a novel splice variant with an opposite effect on the cell cycle.

Authors:  Muhammad Sohail; Jiuyong Xie
Journal:  Mol Cell Biol       Date:  2015-04-13       Impact factor: 4.272

8.  LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.

Authors:  Zahid Q Bonday; Guillermo S Cortez; Michael J Grogan; Stephen Antonysamy; Ken Weichert; Wayne P Bocchinfuso; Fengling Li; Steven Kennedy; Binghui Li; Mary M Mader; Cheryl H Arrowsmith; Peter J Brown; Mohammad S Eram; Magdalena M Szewczyk; Dalia Barsyte-Lovejoy; Masoud Vedadi; Ernesto Guccione; Robert M Campbell
Journal:  ACS Med Chem Lett       Date:  2018-04-23       Impact factor: 4.345

Review 9.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

10.  Critical role of transmethylation in TLR signaling and systemic lupus erythematosus.

Authors:  Virginie Tardif; Yulia Manenkova; Michael Berger; Kasper Hoebe; Jian-Ping Zuo; Chong Yuan; Dwight H Kono; Argyrios N Theofilopoulos; Brian R Lawson
Journal:  Clin Immunol       Date:  2013-03-05       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.